Kibur Medical

Kibur Medical is a private, pre-revenue biotech company developing a novel implantable microdevice platform for in vivo cancer drug testing. Its core technology, the NanoNail™, is implanted into tumors to release microdoses of multiple therapeutics, and upon retrieval, the surrounding tissue is analyzed using multi-omic profiling and machine learning to generate a comprehensive molecular map of drug response. This platform is designed to de-risk oncology drug development by providing unprecedented, physiologically relevant data on drug efficacy and mechanism of action earlier in the pipeline. Kibur has validated its approach through multiple peer-reviewed publications and a partnership with Charles River Laboratories, positioning it as a tool for both pharmaceutical developers and clinical researchers.

NanoNail™ implantable microdevice for in situ, high-throughput pharmaco-phenotyping. It enables simultaneous microdose delivery of up to 20 drugs/drug combinations into a tumor, followed by retrieval and multi-omic (proteomic, genomic, metabolomic) analysis of the response using machine learning.

Kibur operates in a niche but emerging space of in situ functional drug testing. Potential competitors include companies developing ex vivo organoid or tissue slice platforms, as well as those advancing liquid biopsy-based functional assays. Kibur's unique differentiator is its ability to test drugs in the intact, living tumor microenvironment with spatial resolution.